Selection of the Appropriate Package Type Terms and Recommendations for Labeling Injectable Medical Products Packaged in Multiple-Dose, Single-Dose, and Single-Patient-Use Containers for Human Use Guidance for Industry

U.S. Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research (CDER)
Center for Biologics Evaluation and Research (CBER)
Center for Devices and Radiological Health (CDRH)
Office of Combination Products

October 2018
Pharmaceutical Quality/CMC
Selection of the Appropriate Package Type Terms and Recommendations for Labeling Injectable Medical Products Packaged in Multiple-Dose, Single-Dose, and Single-Patient-Use Containers for Human Use Guidance for Industry

Additional copies are available from:
Office of Communications, Division of Drug Information
Center for Drug Evaluation and Research
Food and Drug Administration
10001 New Hampshire Ave., Hillandale Bldg., 4th Floor
Silver Spring, MD 20993-0002
Phone: 855-543-3784 or 301-796-3400; Fax: 301-431-6353
Email: druginfo@fda.hhs.gov
https://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm

Office of Communication, Outreach and Development
Center for Biologics Evaluation and Research
Food and Drug Administration
10903 New Hampshire Ave., Bldg. 71, Room 3128
Silver Spring, MD 20993-0002
Phone: 800-835-4709 or 240-402-8010
Email: ocod@fda.hhs.gov

Office of the Center Director
Center for Devices and Radiological Health
Food and Drug Administration
10903 New Hampshire Ave., Bldg. 66, Room 5431
Silver Spring, MD 20993-0002
Email: CDRH-Guidance@fda.hhs.gov
https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/default.htm

Office of Combination Products
Office of Special Medical Programs
Office of the Commissioner
Food and Drug Administration
10903 New Hampshire Avenue, WO-32 Hub 5129
Silver Spring, MD 20993-0002
(Tel) 301-796-8930 (Fax) 301-796-8619
http://www.fda.gov/CombinationProducts/default.htm

U.S. Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research (CDER)
Center for Biologics Evaluation and Research (CBER)
Center for Devices and Radiological Health (CDRH)
Office of Combination Products

October 2018
Pharmaceutical Quality/CMC
TABLE OF CONTENTS

I. INTRODUCTION............................................................................................................. 1

II. BACKGROUND ............................................................................................................... 2

III. DISCUSSION.................................................................................................................... 3
    Definitions ................................................................................................................................. 3
    1. Single-Dose Container ........................................................................................................... 3
    2. Multiple-Dose Container ..................................................................................................... 3
    3. Single-Patient-Use Container ............................................................................................ 5

IV. LABELING REQUIREMENTS AND RECOMMENDATIONS................................. 6
    A. Change from “single-use” to “single-dose” package type term ........................................... 7
    B. All other changes to a package type term ............................................................................... 7
    C. Changes made to add a package type term to the container/carton labeling (and, in some
cases, the prescribing information) when no package type is included (or listed) .................... 7
    D. Any other proposed changes in package type terminology ................................................... 8
    E. Addition of a discard statement or changes to an existing discard statement ..................... 8
Selection of the Appropriate Package Type Terms and Recommendations for Labeling Injectable Medical Products Packaged in Multiple-Dose, Single-Dose, and Single-Patient-Use Containers\(^1\) for Human Use

Guidance for Industry\(^2\)

This guidance represents the current thinking of the Food and Drug Administration (FDA or Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the FDA office responsible for this guidance as listed on the title page.

I. INTRODUCTION

This guidance provides industry with the Food and Drug Administration’s (FDA’s) recommendations on the selection of appropriate package type terms and selection of appropriate discard statements\(^3\) for injectable medical products for human use, packaged in multiple-dose, single-dose, and single-patient-use containers. Specifically, this guidance provides FDA’s revised definitions for single-dose and multiple-dose containers as well as for the new package type term single-patient-use container.\(^4\) These containers may be part of a drug, a biological product, or a combination product assigned to CDER, CBER, or certain combination products assigned to CDRH.\(^5\) Marketing applications for such products include: New Drug Applications (NDAs), Abbreviated New Drug Applications (ANDAs), Biologics License Applications (BLAs), Premarket Approval Applications (PMAs), Premarket Notifications under section 510(k) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), and requests for classification submitted under section 513(f)(2) of the FD&C Act (De Novo request).

\(^1\) The term \textit{container} in this guidance refers to all package types used for injectable medical products for human use. This guidance does not discuss all package type terms (e.g., \textit{Pharmacy Bulk Package}). Please refer to United States Pharmacopeia (USP) General Chapter <659> \textit{Packaging and Storage Requirements} for other package type terms.

\(^2\) This guidance has been prepared by the Office of Pharmaceutical Quality in the Center for Drug Evaluation and Research (CDER) in cooperation with the Center for Biologics Evaluation and Research (CBER), the Center for Devices and Radiological Health (CDRH), and the Office of Combination Products in the Office of the Commissioner at the Food and Drug Administration.

\(^3\) This guidance is intended to provide recommendations on the selection of discard information for containers. It does not provide information on disposal instructions. Discard information is a statement supported by appropriate data on when to stop using an injectable medical product. Disposal information is a statement on how to safely and appropriately destroy any unused injectable medical product.

\(^4\) For the purpose of this guidance, such products are referred to as \textit{medical products}. Diluents used to reconstitute or dilute human drug and biological products are also considered to be medical products.

\(^5\) See 21 CFR 3.2. Combination products are composed of a drug, device, and/or a biological product. For information on center assignment, see 21 CFR 3.4.
In general, FDA’s guidance documents do not establish legally enforceable responsibilities. Instead, guidances describe the Agency’s current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use of the word *should* in Agency guidances means that something is suggested or recommended, but not required.

II. BACKGROUND

Unsafe injection practices, including the use of needles or syringes for more than one patient or the improper use of medication vials for more than one patient, threaten patient safety and have resulted in multiple blood borne bacterial and viral infection outbreaks. Bacterial and viral infections have been transmitted to patients when single-dose containers were used improperly, the contents became contaminated and these contents were then administered to multiple patients. Failure to follow standard precautions and aseptic techniques has also been associated with several outbreaks of infections involving multiple-dose vials. Examples of such incidents with single-dose and multiple-dose vials are:

- From 1998 through 2008, patient to patient transmission of blood borne pathogens due to unsafe injection practices resulted in 33 outbreaks of viral hepatitis in nonhospital health care settings in the United States.  
  

- According to the Centers for Disease Control and Prevention (CDC), at least 26 incidents involving the improper use of single-dose medications in outpatient settings have occurred over a five year period resulting in the potential exposure of more than 95,000 patients to infectious diseases.  
  

- In 2002, 71 cases of hepatitis C virus (HCV) infection and 31 cases of hepatitis B virus infection were attributed to unsafe needle/syringe practices in an Oklahoma pain clinic.  
  

- In 2008, an investigation of an HCV outbreak in Nevada revealed that reuse of syringes in multiple patients and use of single-use medication vials for multiple patients were the likely mechanisms by which HCV infections were transmitted.  
  
  9 CDC: 2007, Acute hepatitis C virus infections attributed to unsafe injection practices at an endoscopy clinic-Nevada. MMWR 2008; 57:513-7. Available at: [http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5719a2.htm](http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5719a2.htm).

It is evident from the examples described above that single-dose containers, which are intended for use for a single patient, have been used for more than one patient in the past, and that this practice has contributed to many of these bacterial and viral infection outbreaks. Additionally, there is a concern that existing package type terms do not adequately convey that some
Containers (e.g., insulin pens) that provide multiple doses are intended for use for only a single patient.\(^{10}\)

III. DISCUSSION

As part of its review of medical products, FDA clears or approves package type terms and discard statements as part of the labeling of injectable medical products. FDA believes that consistent use of correct package type terms and discard statements for injectable medical products for human use will promote their proper use and provide a foundation for educational efforts to reduce the transmission of blood borne pathogens. The following sections describe the appropriate package type terms for multiple-dose, single-dose, and single-patient-use containers that may be part of injectable drug and biological products for human use, CDER-led, CBER-led, or certain CDRH-led combination products for injection, and diluents used to reconstitute or dilute human drug and biological products.

Definitions

The package type terms “single-dose” container and “multiple-dose” container have been in use for a long time. To provide clarity on the intended use of these terms, the definitions are being revised as follows:

1. **Single-Dose Container:** A single-dose container is a container of a sterile medication\(^{11}\) for parenteral administration (injection or infusion) that is not required to meet the antimicrobial effectiveness testing requirements. A single-dose container is designed for use with a single patient as a single injection/infusion. When space permits, a single-dose container is labeled as such and should include on the label appropriate discard statements. Examples of single-dose containers are vials, ampules, and prefilled syringes.

2. **Multiple-Dose Container:**\(^{12}\) A multiple-dose container is a container of a sterile medication\(^{13}\) for parenteral administration (injection or infusion) that has met antimicrobial effectiveness testing requirements, or is excluded from such testing requirements by FDA regulation.\(^{14}\) A multiple-dose container is intended

\(^{10}\) In March 2009, in response to reports of improper use of insulin pens in hospitals, FDA issued a Safety Alert for health care professionals reminding them that insulin pens are meant for use on a single patient only and are not to be shared between patients. Available at: https://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHealthcareProfessionals/ucm133352.htm.

\(^{11}\) The term sterile medication applies to both active drug products and diluents.

\(^{12}\) The term multi-dose may be used instead of multiple-dose.

\(^{13}\) See footnote 11.

\(^{14}\) Antimicrobial effectiveness testing determines whether the product prevents microbial growth if contamination of the container occurs during patient use conditions. Some injectable chemical formulations may possess sufficient inherent antimicrobial effectiveness characteristics without the addition of a preservative, while other products rely on the addition of a preservative to meet this requirement. However, certain specially designed packaging and delivery systems or certain radiopharmaceuticals with short expiration dates permit the use of preservative-free injectable
Contains Nonbinding Recommendations

to contain more than one dose of the drug product. When space permits, a multiple-dose container is labeled as such. Multiple-dose containers are generally expected to contain 30 mL or less of medication.\textsuperscript{15} The beyond-use date\textsuperscript{16} for an opened or entered (e.g., needle-punctured) multiple-dose container is 28 days, unless otherwise specified by the manufacturer on the label.\textsuperscript{17,18} An example of a multiple-dose container is a vial.

In the vast majority of cases, the package type terms “single-dose” and “multiple-dose” are properly used. However, in some unique situations, a package contains multiple doses of a medical product that is intended to be for use in a single patient. The medical product in this package type may not contain a preservative or be able to pass antimicrobial effectiveness if tested, yet this package type contains multiple doses for use in a single patient. An example of this package type is a drug intended for intrathecal administration that is packaged in a patient-controlled analgesia cartridge. Because the package type is designed to administer multiple doses, the package type term “single-dose” is not appropriate. However, the package type term “multiple-dose” is also inappropriate because the package contents are not able to meet antimicrobial effectiveness testing requirements.

In other cases, the medical products in this package type do contain a preservative and are expected to pass antimicrobial effectiveness if tested, yet the intent is that the package is to be restricted to use by a single patient. In this scenario, referring to the package type as “multiple-dose” does not adequately convey the intent to restrict the use to a single patient. An example of such a product is an insulin pen that contains multiple doses of insulin for individual patient use.

In the past, the term “single-use” container has been used by FDA to describe a package type that contained multiple doses but was intended to be used in a single patient. Unfortunately, the term “single-use” was also inappropriately used as if it were interchangeable with the term “single-dose” which was not the Agency’s original intent. To address this confusion regarding the terminology, the Agency is retiring the term “single-use” and a new package type term “single-patient-use” container, has been created to address the need for describing a package that contains multiple doses of an injectable medical product that is intended to be used in a single patient.

\textsuperscript{15} United States Pharmacopeia-National Formulary (USP-NF-) <659> PACKAGING AND STORAGE REQUIREMENTS, Injection Packaging.
\textsuperscript{16} Beyond-use date (BUD) is the date or time beyond which a product should not be used. See USP-NF <7> LABELING, Expiration Date and Beyond-Use Date.
\textsuperscript{17} See https://www.jointcommission.org/standards_information/jcfaqdetails.aspx?StandardsFaqId=1091&ProgramId=46.
\textsuperscript{18} Vaccines in multiple-dose vials should be used and disposed of according to their FDA approved product labeling. Unless a multiple-dose vial is labeled otherwise, vaccines supplied in multiple-dose vials may be used up to the date of expiry of the product. See also http://www.cdc.gov/mmwr/preview/mmwrhtml/rr6002a1.htm.
3. **Single-Patient-Use Container:** A single-patient-use container is a container of a sterile medication\(^{19}\) for parenteral administration (injection or infusion) that is intended to be used multiple times for a single patient. When space permits, a single-patient-use container is labeled as such and should include on the label appropriate discard statements. Examples of single-patient-use containers are patient controlled analgesia cartridges and certain pens for injection.

For multiple-dose and single-patient-use containers, the antimicrobial effectiveness testing results, if performed, will be used to support the labeled beyond-use date or discard statements.

The following diagram illustrates how the appropriate package type term for an injectable medical product can be determined:

* Use of the term “single-dose” container does not imply the entire contents of the container constitute a single dose. In some instances, a single-dose container may contain more drug than is required for a single dose or multiple vials may be needed to obtain a single dose. For example, for a medical drug product that is dosed based on body weight, or due to the required overfill in vials and ampules, there may be excess amount constituting more than one dose in the container, which should be discarded. Please refer to FDA’s guidance for industry on *Allowable Excess Volume and Labeled Vial Fill Size in Injectable Drug and Biological Products*.\(^{20}\) Furthermore, although dosed over an extended time period, infusion containers (large or small volume) are considered single-dose containers because they are designed for use with a single patient as a single infusion.

---

\(^{19}\) See footnote 11.

\(^{20}\) This guidance is available on the Internet at [https://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm](https://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm) under Guidances (Drugs).
IV. LABELING REQUIREMENTS AND RECOMMENDATIONS

Applicants should determine the proper package type term (“single-dose,” “multiple-dose,” or “single-patient-use”) for injectable medical products for human use and use only the correct term for the package type throughout the labeling. FDA recommends that the appropriate package type term appear on all components of the labeling of injectable medical products for human use so the user will be able to easily identify the package type. This includes the container label and carton labeling, prescribing information, and where applicable, labeling intended for the patient.21

The package type term “single-dose” is required to appear on the container labels of single-dose injectable medical products that have a United States Pharmacopeia (USP) monograph, when space permits (FD&C Act section 502(g) (21 U.S.C. 352(g)).22 When space does not permit the “single-dose” term to appear on such products’ container labels, then according to 21 CFR 201.10(i)(2), it must appear on the carton or other outer container or wrapper, if space permits, or in the prescribing information. In FDA’s experience, there has always been sufficient space to include this information on the carton labeling.

When space permits, the appropriate package type term should appear on the container label of multiple-dose and single-patient-use injectable medical products, as well as single-dose injectable medical products that do not have a USP monograph. If there is insufficient space to include this information on the container label, the package type term should appear on the carton labeling where it will be easily visible.

When appropriate, the prescribing information for single-patient-use and single-dose injectable medical products should include a discard statement.23 The discard statement should also be included on the container label and carton labeling, when space permits. For example, single-dose container labeling should typically include the statement “Discard unused portion.”

Multiple-dose containers do not normally have a discard statement because the beyond-use date is assumed to be 28 days for an opened or entered (e.g., needle-punctured) multiple-dose container, unless otherwise indicated.24 If the beyond-use date is other than 28 days for a product in a multiple-dose container, an appropriate discard statement (supported by appropriate data) should be included on the container label, carton labeling, and in the

21 Examples of sections within the prescribing information for drug products where the package type term may appear include, but are not limited to: DOSAGE AND ADMINISTRATION, DOSAGE FORMS AND STRENGTHS, DESCRIPTION, and HOW SUPPLIED/STORAGE AND HANDLING (21 CFR 201.56 and 201.57).
22 21 U.S.C. section 352(g); The following statement “A single-dose container shall be labeled as such…” appears in United States Pharmacopeia-National Formulary (USP-NF), <7> Labeling, and a similar phrase “…a single-dose container is labeled as such…” appears in <659> Packaging and Storage Requirements.
23 This statement should be placed in the DOSAGE AND ADMINISTRATION, Preparation Instructions section of the prescribing information and, when applicable, in patient labeling such as the INSTRUCTIONS FOR USE. (21 CFR 201.56, and 201.57).
24 See footnotes 17, 18.
prescribing information. Examples of statements that might appear on multiple-dose containers include:

- “Discard within XX hours after opening or after assembly” or
- “After first use, refrigerate or keep at a temperature not greater than XX for XX days.”

The Agency recommends that applicants make the necessary labeling changes to follow these recommendations within two years of the publication of this guidance. All submissions (annual reports and supplements) should clearly identify the change(s) being made. In addition, a supplement submission to follow the recommendations in the guidance should be identified as “Labeling Changes to Follow the Package Type Term Guidance.” For approved applications, changes made to labeling to follow the recommendations in this guidance should be submitted to the FDA as described below.25

**A. Change from “single-use” to “single-dose” package type term**

For a drug product that was designed and otherwise labeled for use with a single patient as a single injection/infusion, a change from the package type term “single-use” to “single-dose” to accurately reflect the package type should be submitted in an annual report. See 21 CFR 314.70(d)(2)(x); 21 CFR 314.94(a)(8)(iv) and 21 CFR 601.12(f)(3)(i)(A).26

**B. All other changes to a package type term**

ALL other changes to a package type term, including a change from the package type term “single-use” to “single-patient-use,” as well as a change from “multiple-dose” to “single-patient-use” should be submitted as a “Prior Approval Supplement” (PAS) for NDAs and BLAs only. See 21 CFR 314.70(b)(2)(v)(A); and 21 CFR 601.12(f)(1).

After FDA approval of a PAS for an NDA, the holders of any ANDAs that relied upon the NDA as the reference listed drug (RLD) are required to submit conforming labeling revisions. See 21 CFR 314.94(a)(8)(iv) and 21 CFR 314.150(b)(10). FDA is specifically requesting that these conforming ANDA labeling revisions be submitted in a “Changes Being Effected” (CBE-0) supplement. See 21 CFR 314.70(c)(6)(iii)(E). If approval of the NDA for the RLD has been withdrawn, the corresponding ANDA holders should submit a PAS to propose changes to a package type term.

**C. Changes made to add a package type term to the container/carton labeling (and, in some cases, the prescribing information) when no package type is included (or listed)**

---

25 This information is specific for NDAs, ANDAs, and BLAs. For information on other cleared or approved medical products regulated by CBER or CDRH, contact the appropriate Center.

26 This discussion of potential regulatory pathways for submission assumes that the change in package type term from “single-use” to “single-dose” is the only change being made to the labeling. Other changes may require submission of a supplement.
1. If the prescribing information already includes the appropriate assigned package type but the container/carton labeling lacks the designation for some reason other than lack of space, NDA, BLA, and ANDA holders may submit the addition of the package type term to the container/carton labeling in an annual report under 21 CFR 314.70(d)(2)(x), and 21 CFR 601.12(f)(3)(i)(A), as long as the package type term being added to the container/carton labeling is the same correct term that has already been included in the approved prescribing information. The same procedure applies if the container/carton labeling includes the appropriate assigned package type but the prescribing information lacks the designation.

2. If neither the container/carton labeling nor the prescribing information has a package type term listed, NDA and BLA holders should submit a PAS to add the appropriate term to the container/carton labeling and prescribing information, see 21 CFR 314.70(b)(2)(v)(A) and 21 CFR 601.12(f)(1). After FDA approval of the PAS for the NDA RLD, corresponding ANDA holders are required to submit conforming labeling revisions. See 21 CFR 314.94(a)(8)(iv) and 21 CFR 314.150(b)(10). FDA is specifically requesting that these conforming ANDA labeling revisions be submitted in a CBE-0 supplement. See 21 CFR 314.70(c)(6)(iii)(E). If approval of the NDA for the RLD has been withdrawn, the corresponding ANDA holders should submit a PAS to propose a package type term.

D. Any other proposed changes in package type terminology

For any other proposed changes regarding package type terms, please contact the Agency.27

E. Addition of a discard statement or changes to an existing discard statement

1. Discard unused portion
   The addition of or change to the phrase “Discard unused portion” in the labeling of a single-dose container should be submitted in an annual report. See 21 CFR 314.70(d)(2)(x); 21 CFR 314.94(a)(8)(iv) and 21 CFR 601.12(f)(3)(i)(A).28

2. Any other proposed change in a discard statement
   For any other proposed change regarding a discard statement, please contact the Agency.29

---

27 See footnote 25.
28 See footnote 25.
29 When the submission is for an NDA or BLA, contact the specific drug product’s review division with questions. When the submission is for an ANDA, submit questions as a General Correspondence to the application.